Recruiting
A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT07851259· Phase 2· Genentech, Inc.· Source
Recruiting
Trial to Investigate the Safety and Effectiveness of the KI-362-US1 (YP2.2VM) Intraocular Lens (IOL) in Adult Participants for Correction of Aphakia Following Cataract Extraction
NCT07650201· Kowa Research Institute, Inc.· Source
Contact: Director, Clinical Operations
Recruiting
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
NCT07913074· Phase 2· Tavo Biotherapeutics· Source
Contact: Joel Thompson
Recruiting
A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
NCT07867080· Phase 3· 4D Molecular Therapeutics· Source
Contact: 4DMT Patient Advocacy
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
NCT07425522· Phase 1· Genentech, Inc.· Source
Active, not recruiting
COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
NCT07449936· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Recruiting
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
NCT06659445· Phase 2· ONL Therapeutics· Source
Contact: Study Coordinator
Recruiting
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT07064759· Phase 3· 4D Molecular Therapeutics· Source
Contact: 4DMT Patient Advocacy
Recruiting
Evaluation of Cataract Surgery Outcomes in Patients With Prior Laser Vision Correction Implanted With the CT LUCIA Lens
NCT07084545· Carl Zeiss Meditec AG· Source
Contact: Mishael Benjamin
Recruiting
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
NCT06962839· Phase 2· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988· Phase 3· 4D Molecular Therapeutics· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
NCT06770933· Phase 2· Vantage Biosciences Ltd· Source
Active, not recruiting
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
NCT06769048· Phase 2· Boehringer Ingelheim· Source
Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Active, not recruiting
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
NCT06668064· Phase 3· EyePoint Pharmaceuticals, Inc.· Source
Recruiting
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT06635148· Phase 2/3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
NCT06556368· Phase 3· Kodiak Sciences Inc· Source
Active, not recruiting
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816· Phase 3· Annexon, Inc.· Source
Active, not recruiting
4D-150 in Patients With Diabetic Macular Edema
NCT05930561· Phase 2· 4D Molecular Therapeutics· Source
Recruiting
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
NCT05626114· Phase 2· Genentech, Inc.· Source
Active, not recruiting
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7497372 in Participants With Diabetic Macular Edema (DME)
NCT06847854· Phase 1· Genentech, Inc.· Source
Active, not recruiting
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
NCT05224102· Phase 4· Genentech, Inc.· Source
Active, not recruiting
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
NCT04853251· Phase 4· Genentech, Inc.· Source
Active, not recruiting
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
NCT04108156· Phase 3· Hoffmann-La Roche· Source